Evidence map›Paper›PMID 32370195›Full record

ReviewJournal of clinical medicine2020

Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities.

Angela M Jarrett, Danial Faghihi, David A Hormuth Ii, Ernesto A B F Lima, John Virostko, George Biros, Debra Patt, Thomas E Yankeelov

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
1.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Stochastic Evolutionary Control in Heterogeneous Populations.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Evolutionary antifragile therapy.bioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Article
  11. Identifiability and model selection frameworks for models of high-grade glioma response to chemoradiation.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Angela M JarrettOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
Danial FaghihiDepartment of Mechanical and Aerospace Engineering, The University at Buffalo, Buffalo, NY 14260, USA.
David A Hormuth IiOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
Ernesto A B F LimaOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
John VirostkoLivestrong Cancer Institutes, The University of Texas at Austin, Austin, TX 78712, USA.
George BirosOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
Debra PattTexas Oncology, Austin, TX 78731, USA.
Thomas E YankeelovOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
Livestrong Foundation · USThe University of Texas at Austin · USTexas Oncology · USUniversity at Buffalo, State University of New York · US

Funding

Statistical atlases of brain tumor MRI:do imaging phenotypes predict progression?R01NS042645 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI DAVATZIKOS, CHRISTOS · 2002 to 2024
$8.7M
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant TherapyU01CA142565 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KARCZMAR, GREGORY S., NANDA, RITA · 2010 to 2019
$4.5M
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2M
Quantitative Multiscale Imaging to Optimize Cancer Treatment StrategiesR01CA186193 · NCI · VANDERBILT UNIVERSITY · PI QUARANTA, VITO, RERICHA, ERIN C · 2014 to 2019
$3.1M
Image Driven Multi-Scale Modeling to Predict Treatment Response in Breast CancerU01CA174706 · NCI · VANDERBILT UNIVERSITY · PI QUARANTA, VITO, YANKEELOV, THOMAS E · 2013 to 2018
$2.5M
American Association of Physicists in Medicine 2018 Research Seed GrantCancer Prevention and Research Institute of Texas RR160005NCI NIH HHS R01CA186193NCI NIH HHS U01CA142565NCI NIH HHS U01CA174706NCI NIH HHS U24CA226110NINDS NIH HHS R01 NS042645
6 · The paper itself

Abstract

Optimal control theory is branch of mathematics that aims to optimize a solution to a dynamical system. While the concept of using optimal control theory to improve treatment regimens in oncology is not novel, many of the early applications of this mathematical technique were not designed to work with routinely available data or produce results that can eventually be translated to the clinical setting. The purpose of this review is to discuss clinically relevant considerations for formulating and solving optimal control problems for treating cancer patients. Our review focuses on two of the most widely used cancer treatments, radiation therapy and systemic therapy, as they naturally lend themselves to optimal control theory as a means to personalize therapeutic plans in a rigorous fashion. To provide context for optimal control theory to address either of these two modalities, we first discuss the major limitations and difficulties oncologists face when considering alternate regimens for their patients. We then provide a brief introduction to optimal control theory before formulating the optimal control problem in the context of radiation and systemic therapy. We also summarize examples from the literature that illustrate these concepts. Finally, we present both challenges and opportunities for dramatically improving patient outcomes

Indexed as

cancer treatmentmathematical modeloptimizing responsepredicting response

Identifiers

PMID32370195
PMCPMC7290915
OpenAlexW3021893451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.